Inclusion criteria | Exclusion criteria |
---|---|
All studies | All studies |
Published 2003–2014 | Conducted exclusively in HIV co-infected patients |
Published in English | Conducted exclusively in pediatric patients |
Conducted in patients with chronic HCV | Wrong publication type: letters, case studies, editorials and commentaries were excluded |
 | Conducted exclusively in patients with genotypes 2, 3, 4, 5 or 6 |
Clinical studies | Clinical studies |
Minimum 1Â year post-treatment follow-up | <100 patients |
Report hard clinical endpoints (e.g. overall mortality, incidence of hepatocellular carcinoma) | Endpoints limited to biochemical parameters only (e.g. aminotransferase levels only) |
Health economic studies | Health economic studies |
Assessing cost-effectiveness of protease inhibitors versus pegIFN plus ribavirin, pegIFN, IFN or no treatment | Assessing pegIFN plus ribavirin versus pegIFN, IFN or no treatment |
Quality of life studies | Quality of life studies |
Presentation of quantitative results using a validated quality of life instrument | Â |